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MELANOMA AND NON-MELANOMA MALIGNANCIES  
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ABSTRACT 
 Overexposure to UV (ultraviolet) radiation has been linked to a number of 
deleterious effects on human health, particularly epidermal malignancies, which consist 
of both melanoma and non-melanoma skin cancers, basal cell carcinoma and squamous 
cell carcinoma. In the 1950’s, an epidermal compound known as Urocanic Acid (UCA) 
was discovered whose trans isoform was shown to display photoprotective effects against 
UV radiation. Not long after, the cis-UCA isomer was found to act as a mediator of 
immune suppression, causing UCA to be removed from all cosmetic products on the 
commercial market, most notably sunscreen. Numerous studies conducted after this 
finding further corroborated cis-UCA’s immunosuppressive properties, showing evidence 
for the ability of cis-UCA to inhibit contact hypersensitivity responses, delayed-type 
hypersensitivity responses, and allograft rejection. Early evidence for a mechanism of 
action behind cis-UCA’s immunosuppressive properties were widespread, including 
modulation of antigen-presenting cells, interaction with histamine receptors, and 
regulation of cytokine expression. The immunosuppressive nature of cis-UCA quickly 
became associated with an ability to facilitate cancerous progression, particularly 
regarding epidermal malignancies. Interesting theories were raised about the evolutionary 
basis for cis-UCA’s immunosuppressive nature, including speculation that cis-UCA was 
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meant to induce immunosuppression following ultraviolet exposure in order to prevent 
autoimmune responses against sunburned epidermal cells. After the turn of the 20th 
century, new research continued to facilitate modern day understanding of the role of 
UCA. Evidence showed that UCA was ultimately derived from filaggrin within the 
stratum corneum, interacted with key immune effectors including T-lymphocytes and 
Langerhans cells, and potentially contributed to acidification of the stratum corneum. 
Despite the negative reputation cis-UCA has received in regards to facilitating skin 
cancer evasion of the immune system, research has shown that its immunosuppressive 
effects may allow it to serve as potent anti-inflammatory therapeutic. In regards to skin 
cancer, targeting of UCA as a therapeutic varies widely. Some have suggested using 
UCA as a measure of sunscreen efficacy, as an indirect target that when inhibited can 
reduce tumor growth, and as a biomarker for skin cancer risk. Others have begun 
developing UCA-based mimics that retain the benefits of UCA, while avoiding any 
deleterious effects. The role of UCA in non-melanoma and melanoma malignancies is not 
well understood, making targeting of UCA as a therapeutic challenging. The aim of this 
paper is to comprehensively review the scientific literature regarding the pre-21st century 
history of UCA, followed by an in-depth analysis of post-21st century research. The 
objective is to determine the overall potential of UCA to serve as a therapeutic target for 
UV-associated health conditions, most notably dermatologic malignancies. 
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INTRODUCTION 
 
Health Effects of UV Radiation 
 Overexposure to ultraviolet (UV) radiation is a critical environmental stressor that 
has been linked to a plethora of deleterious effects on human health. Skin damage 
associated with premature aging, ocular impairment such as cataracts, and neoplastic 
changes are among some of the major sun-related health concerns, summarized in Table 
1 (Last, 1993). Additionally, UV radiation has been correlated with immune suppression, 
further increasing susceptibility to malignant transformation and contraction of infectious 
disease (Douki, 2016; Last, 1993). 
 
Table 1. Biological effects of ozone depletion/ultraviolet irradiation. The effects of 
increased ultraviolet irradiation due to ozone depletion impact both global ecological 
landscapes and human health. On an ecological scale, impaired growth of crops has 
major consequences, including hunger and starvation, for all living organisms. For human 
health, increase in risk of skin cancer, both non-melanoma and melanoma forms, are at 
the severest ends of the spectrum. Taken from Last, 1993. 
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Skin cancer is one of the most common forms of malignancy in the United States, 
which includes both melanoma and non-melanoma skin cancers, basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC) (Last, 1993). It is projected that one in every 
five individuals in the US will develop skin cancer within their lifetime and nearly 10,000 
people are diagnosed daily (Skin Cancer, n.d.). While survival rates for skin cancer are 
high, particularly for non-melanoma malignancies, current mortality rates of nearly 
10,000 people per year nationwide and 65,000 people per year worldwide in addition to 
the tens of billions of dollars spent per year on treatment serve as a strong basis behind 
innovative research strategies in advancing prevention, detection, and treatment of skin 
neoplasms (Skin Cancer, n.d.). 
 While UV radiation comprises wavelengths between 250 to 400nm, the subtype 
most associated with development of harmful biological effects is UVB radiation (280 to 
320nm) and UVA (320 to 400nm) to a lesser extent (Douki, 2016; De Fabo, 1996). The 
carcinogenicity of UV radiation is most well-known for its’ propensity to induce DNA 
damage, particularly in keratinocytes, which gives rise to BCC and SCC, and 
melanocytes, which gives rise to melanoma (Douki, 2016). The two major forms of DNA 
damage are pyrimidine dimers, most notably cyclobutane pyrimidine dimers (CPDs), and 
oxidative damage (Douki, 2016). Pyrimidine dimers can be formed through either direct 
absorption of UVB and UVA irradiation by DNA, a potent endogenous chromophore, or 
by photosensitizers, endogenous or exogenous chromophores, which induce changes in 
DNA bases Douki, 2016; Young, 1997). Oxidative damage is produced when absorption 
of UVA and UVB irradiation by cellular components results in the formation of reactive 
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oxygen species and the subsequent degradation of key cellular macromolecules including 
proteins and lipids (Douki, 2016). Inherent DNA repair mechanisms exist to correct 
damage to DNA and prevent mutations from accumulating during DNA replication; 
nucleotide excision repair (NER) is responsible for repairing pyrimidine dimers and base 
excision repair (BER) repairs oxidative DNA modifications. Therefore, the overall 
persistence of DNA damage and their susceptibility to develop into DNA mutations 
depends on the balance between damage formation and efficiency of DNA repair 
mechanisms (Douki, 2016).  
 
Figure 1. Production of Pyrimidine Dimers. One of the primary damaging effects done to 
DNA by ultraviolet radiation is the production of pyrimidine dimers. These result in kinks and 
lesions in the DNA backbone that, if left unfixed by DNA repair mechanisms, can result in 
deleterious DNA mutations. Taken from Quinet et al., 2018. 
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Rise of Urocanic Acid 
 Because the cell types most vulnerable to neoplastic malformations, keratinocytes 
and melanocytes, reside in the stratum basale, the deepest layer of the epithelium, they 
receive protection from the barrier created by the remaining four layers above. These 
layers’ guard against UV damage by direct reflection of radiation as well as absorption by 
endogenous chromophores (Barresi et al. 2011). In the 1950’s, a novel link was found 
between UV radiation and a compound known as Urocanic acid (UCA) (Eckhart, 2016). 
This molecule was found to reside in the most superficial layer of the epidermis, the 
stratum corneum, and it was established the trans isoform served as an efficient absorber 
of UV radiation (Young, 1997). The novel ability of trans-UCA to act as a natural 
protectant against solar irradiation quickly resulted in it being marketed in various 
cosmetic and sunscreen products (Young, 1997). It was later taken off the market in the 
1990’s, when it was discovered that the cis isoform of UCA displays immunosuppressive 
properties; this finding was supported by a well-known study conducted by De Fabo and 
Noonan in 1983 (De Fabo, 1996). Although further research into both the protective 
effects and immunosuppressive effects of various isoforms of UCA dwindled in the 
following years, there still existed great debate and controversy regarding the beneficial 
versus harmful effects of UCA. Recent research has revitalized the possibility of UCA in 
serving a valuable role in protection against UV radiation and as a potential therapeutic 
target against both non-melanoma and melanoma skin cancers (Barresi et al., 2011).    
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SPECIFIC AIMS 
 
 The controversial role of Urocanic Acid as both a photoprotectant and 
immunosuppresor is currently still under debate. The following comprehensive review of 
scientific literature serves to accomplish several objectives. First, a condensed description 
of the history of Urocanic Acid research is provided, emphasizing the factors that have 
contributed to the modern day debate regarding this chromophore. Second, this thesis 
aims to conduct an in-depth analysis of the current research regarding the revitalized 
support of UCA in serving as a potent photoprotectant against UV radiation. Both in vitro 
and in vivo studies will be analyzed, including current Phase 1 clinical trials. In addition, 
both benefits and risks will be extensively researched. Lastly, the final objective of this 
review is to conclude on the overall potential of UCA to serve as a therapeutic target for 
UV-associated health conditions, most notably dermatologic malignancies.  
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HISTORY OF UROCANIC ACID 
 
Discovery and Popularity 
 
One of the main functions of the epidermal layer is photoprotection, which is 
carried out by light-absorbing compounds, including lipids, keratins, melanin, and 
porphyrins (Baden & Pathak, 1967). In the early 1950’s, a compound known as Urocanic 
acid (UCA) was identified as an additional photoprotective constituent of the epidermis. 
The very first description of UCA dates back to an 1874 study by Jaffe, where the 
compound now known to be Urocanic acid was found in the urine of canines (Norval, 
Simpson, & Ross, 1989). Numerous studies beginning in the early 1950’s identified the 
presence of epidermal UCA using techniques including chromatography, 
spectrophotometry, and staining (Norval et al., 1989). Zenisek et al. found UCA in 
human sweat, Tabachnick found UCA in guinea pig epidermis, and Baden and Pathak 
found UCA in the epidermis of a murine model (Baden & Pathak, 1967; Tabachnick, 
1957; Zenisek, Kral, & Hais, 1955). Finally, in 1961, Everett et al. found UCA present in 
human epidermal layers (Everett, Anglin, & Bever, 1961). 
Accounting for roughly 0.7% of the dry weight of the human epidermis, UCA is a 
major absorber of light in the UV range (Baden & Pathak, 1967). UCA exhibited 
absorption profiles that were either stronger than or equal to current sunscreens available 
on the commercial market, prompting researchers to speculate on its’ pharmacological 
potential (Zenisek et al., 1955). Following the discovery of UCA, this pushed many 
researchers during the 1950’s to test the potential of UCA to act as a natural sunscreen 
against erythema-producing radiation. Erythema is a dark reddening of the skin caused by 
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increased blood flow to dermal capillaries; one cause of erythema is solar radiation, 
which results in the commonly known sunburn. A 1957 study by Tabachnick showed that 
UCA was responsible for 80% of all UV-absorption that occurred in guinea pig 
epidermal samples (Tabachnick, 1957). Additionally, a later 1961 study by Everett et al. 
showed that a formulation containing 5% UCA was able to confer erythema protection to 
human skin (Everett et al., 1961). To test the hypothesis that UCA could be utilized as an 
effective sunscreen, Baden & Pathak treated subjects with oral, intradermal, and topical 
applications of UCA followed by solar radiation (Baden & Pathak, 1967). They found 
that subjects treated with topical UCA received sunburns that were half as severe as 
controls who did not receive UCA (Baden & Pathak, 1967). They also found that oral and 
intradermal routes of administration were ineffective in protecting against UV irradiation 
(Baden & Pathak, 1967).  
 
Figure 2. Trans and Cis Isoforms of Urocanic acid. Urocanic acid possesses two 
isoforms: the trans (E) resting form and the cis (Z) active form. Photoisomerization from 
the trans to cis forms is induced by UV irradiation. Taken from Mohammad, 2002. 
 
 
During this time, it was also found that UCA has two forms, the trans (E) and cis 
(Z) isomers. Trans-UCA is the form normally found in the epidermis under resting 
conditions, but UV absorption induces isomerization from the trans to cis isomer (Everett 
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et al., 1961). This isomerization has been shown to be most effective at UV radiation 
wavelengths less than 320nm (Anglin, Bever, Everett, & Lamb, 1961). Baseline levels of 
trans-UCA in the epidermis vary widely, but median levels hover at roughly 4 μg/cm2 
(Norval, McIntyre, Simpson, Howie, & Bardshiri, 1988). In addition to UV irradiation 
inducing isomerization from trans-UCA to cis-UCA, it also increases the total amount of 
UCA in the stratum corneum (Hais & Strych, 1969).  
Production of UCA requires deamination of histidine via an enzyme known as 
histidase, or histidine-ammonia lyase (Mehler & Tabor, 1953). The histidine from which 
UCA is derived, mainly comes from keratohyalin granules located in the stratum 
corneum (Scott, 1981; Scott, Harding, & Barrett 1982). Histidase is synthesized in the 
spinosum and granulosum layers of the epidermis and activate when reaching the stratum 
corneum layer (Norval et al., 1989). This enzyme is known to be present in sufficient 
quantities only in the stratum corneum layer of the epidermis and in the liver (Mehler & 
Tabor, 1953). This corresponds to findings that show UCA is only found in appreciable 
quantities of the stratum corneum layer of the epidermis and in the liver (Baden & 
Pathak, 1967). Importantly, in the liver, UCA is further broken down via the urocanase 
enzyme in a degradative pathway (Feinberg & Greenberg, 1958). Therefore, the presence 
of UCA in the liver can be considered relatively transient and the compound does not 
accumulate with this hepatic system. Conversely, the enzyme urocanase is not found in 
sufficient amounts in the epidermis, and thus UCA can accumulate with the epidermal 
layers, specifically the stratum corneum (Norval et al., 1989). One study illustrated that 
nearly six to twelve times as much histidine was deaminated into UCA compared to the 
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amount used for protein synthesis in the epidermis (Baden & Pathak, 1967). The reason 
for this is that histidase activity is observed to increase with increased UV exposure 
(Baden & Pathak, 1967). After exposure to UV radiation, levels of the cis-UCA remain 
increased for up to three weeks before being eliminated by desquamation at the stratum 
corneum or sweat-based excretion (Norval & El-Ghorr, 2002).  
 
 
 
Figure 3. Production of Urocanic Acid by Histidase. Histidase, is responsible for 
converting the amino acid, Histidine, into Urocanic Acid. Histidase is many found in the 
stratum corneum layer of the epidermis and in the liver. Histidine can also be converted 
into Histamine by Histidine Decarboxylase. Taken from Norval & El-Ghorr, 2002. 
 
 
Health Concerns and Subsequent Withdrawal 
 
Immunosuppression: De Fabo and Noonan   
In the early 1980’s, a novel finding was published by De Fabo and Noonan 
showing the immunosuppressive effects of UCA (De Fabo & Noonan, 1983). It was later 
elucidated that the cis isomer of UCA was responsible for this immunosuppression. The 
work by De Fabo and Noonan focused on the relationship between UCA and carcinoma 
induced by UV radiation (De Fabo & Noonan, 1983). Firstly, it is necessary to recognize 
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that UV radiation plays two main roles in the induction of skin cancer. The first role is 
neoplastic transformation as a result of genetic mutagenesis from radiation. The second is 
induction of localized and systemic immunosuppression, which assists malignant cells in 
invading the immune system. It had been found that UV-radiation, in the range of 250 to 
320 nm, resulted in activation of suppressor T-cells and antigen-specific suppressor cells 
(Kripke, 1984). De Fabo and Noonan were interested in discovering how UV radiation, 
which does not penetrate beneath the dermal layer of the skin, can result in formation of 
systemic immune suppression (De Fabo & Noonan, 1983). 
As aforementioned above, De Fabo and Noonan had previously found that narrow 
band UV radiation in the 250 to 32 nm range induced immunosuppression, by observing 
the systemic suppression of contact hypersensitivity in response to TNCB (2-chloro-l,3,5-
trinitrobenzene) in murine models (De Fabo & Noonan, 1983). TNCB is an agent known 
to induce contact hypersensitivity. They concluded that this suppression occurred 
independently of epidermal damage and erythema, suggesting that the suppression was 
not caused by an inflammatory response to UV radiation (De Fabo & Noonan, 1983). De 
Fabo and Noonan also ruled out antigen-presenting cell (APC) defects and damage to 
epidermal Langerhans cells by UV radiation (De Fabo & Noonan, 1983). Their 
hypothesis was that a photoreceptor was present in the epidermis responsible for 
absorbing UV radiation and subsequently activating a signal transduction cascade that 
would lead to the production of suppressor immune cells (De Fabo & Noonan, 1983). 
This hypothesis was further strengthened after De Fabo and Noonan found that removing 
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the outermost layer of the epidermis, the stratum corneum, prevented induction of 
systemic immune suppression (De Fabo & Noonan, 1983).   
Using this information, De Fabo and Noonan created a model, postulating that a 
photoreceptor exists in the stratum corneum layer of the epidermis that upon exposure to 
UV radiation, transduces a biochemical signal that activates T-suppressor and antigen-
specific suppressor cells (De Fabo & Noonan, 1983). In this way, the unknown 
photoreceptor was hypothesized to act similarly to the well-known photoreceptor, 
Rhodopsin. They ruled out other biochemical compounds found in the stratum corneum, 
including nucleic acids, lipids, amino acids, and keratin (De Fabo & Noonan, 1983). 
Components of the stratum corneum were narrowed down until only one realistic 
possibility remained, UCA. It was found that the absorption of UCA was similar to the 
action spectrum observed during immunosuppression (De Fabo & Noonan, 1983). 
Further supporting the likelihood that UCA was the unknown photoreceptor that De Fabo 
and Noonan were looking for, was the location of UCA in the stratum corneum, the 
photochemical properties of UCA as a known absorber of UV and radiation.  
Thus, De Fabo and Noonan tested this hypothesis using a murine model and 
found that mice with intact stratum corneum layers but reduced levels of UCA did not 
display immunosuppression when compared to controls with baseline levels of UCA (De 
Fabo & Noonan, 1983). The mechanism of action proposed by De Fabo and Noonan was 
that following UV radiation, UCA is activated and enters systemic circulation, where it 
results in a decrease of antigen-presenting cells and subsequent activation of suppressor 
cells upon exposure to antigen (De Fabo & Noonan, 1983). Following this finding, 
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research investigating the immunosuppressive properties of UCA and the subsequent 
impact it would have on human health skyrocketed. Numerous studies were also done on 
the mechanism of action of UCA in immunosuppression and its’ relationship to disease 
pathologies.  
Immunosuppression: Preliminary Research  
The evidence that UCA, specifically cis-UCA, was capable of causing immune 
defects grew rapidly. Ross et al. utilized a murine model of HSV to show that topical 
application of subcutaneous injection of cis-UCA to epidermal cells from irradiated mice 
resulted in immunosuppression of delayed type hypersensitivity responses (DTH) to 
herpes simplex virus (HSV) (Ross, Howie, Norval, Maingay, & Simpson, 1986; Ross, 
Howie, Norval, & Maingay, 1987). They also found that the percentage of cis-isomer 
present correlated with the percentage degree of suppression of DTH, i.e. in a dose-
dependent manner (Ross et al., 1986; Ross et al., 1987). Analysis of subsequent 
production of suppressor immune cells led these researchers to believe that both local and 
systemic immunosuppressive signals are generated by cis-UCA. In 1988, Norval et al. 
expanded on this finding by discovering that this immunosuppression is time-sensitive 
(Norval et al., 1988). They found that the viral infection needed to occur at least more 
than five hours and less than two weeks post-UV radiation (Norval et al., 1988).  
The majority of studies illustrating immunosuppression mediated by UCA were 
focused on topical application. This was critical as it mimicked the main route of 
exposure individuals would experience on a daily basis, e.g. through cosmetic products 
containing UCA. In 1989, Reeve et al. showed that UCA applied topically to UV-
irradiated hairless mice resulted in suppression of contact type hypersensitivity to 
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oxazolone (Reeve, Greenoak, Canfield, Boehm-Wilcox, & Gallagher, 1989). They also 
investigated the impact of topical application of UCA to hairless mice on progression of 
malignant growth (Reeve et al., 1989). It was found that mice treated with topical UCA 
exhibited increased total counts of UV-induced tumor masses and increased degree of 
malignancy when exposed to chronic doses of UV radiation (Reeve et al., 1989). This 
illustrated a definitive link between cis-UCA and induction of epidermal malignancy.  
The popularity of UCA and its associated sunscreening effects resulted in its 
addition to commercial sunscreens. In 1991, Reeve et al. performed a study where they 
showed that solar radiation of areas treated with UCA-containing cosmetics resulted in 
the formation of cis-UCA (Reeve & Mitchell, 1991). Furthermore, they found that UCA-
containing cosmetic lotion applied to the murine epidermis resulted in 
immunosuppression of contact hypersensitivity to DNFB (Reeve & Mitchell, 1991). A 
later 1992 study by Gruner et al. illustrated that cis-UCA displayed similar effects to 
PUVA, in inducing immunosuppression during murine heart allografts (Gruner et al., 
1992). Control grafts without either PUVA or cis-UCA treatment observed rejection of 
the allograft within two weeks’ time (Gruner et al., 1992). Groups treated with either 
PUVA or cis-UCA preventing rejection of the allograft in up to 50% of mice (Gruner et 
al., 1992).  
In the late 1990’s, researchers began using anti-cis-UCA antibodies to test the 
impact of blocking cis-UCA action on immunosuppression. In 1995, Kondo et al. found 
that an intradermal injection of cis-UCA resulted in immune suppression of CHS when 
later treated with DNFB (Kondo et al., 1995). For mice that were given anti-cis-UCA 
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antibodies prior to UV radiation exposure, the amount of immunosuppression was 
reduced and the CHS response was marginally restored (Kondo et al., 1995. Another 
study by Finlay-Jones & Hart in 1998 found that commercial sunscreens partially blocked 
the isomerization of trans-UCA to cis-UCA and subsequently partially blocked systemic 
immunosuppression (Finlay-Jones & Hart, 1998). Importantly, complete blockage of 
immunosuppression did not occur unless mice were pre-treated with anti-cis-UCA 
antibodies (Finlay-Jones & Hart, 1998).   
During this period, studies continued to surface demonstrating the 
immunosuppressive nature of cis-UCA. A study by El-Ghorr et al. in 1997 tested the 
effects of chronic trans-UCA and cis-UCA on murine epidermal skin health (El-Ghorr & 
Norval, 1997). Over a four-week period, they found that only mice treated with cis-UCA 
presented with systemic immunosuppression, reduced thymic weight, and increased 
lymph node weight (El-Ghorr & Norval, 1997).  
Early Evidence for a Mechanism of Action 
A Receptor for Cis-UCA  
Studies were conducted in the late 1980’s demonstrating that minute fluctuations 
in cis-UCA concentration could result in appreciable amounts of immunosuppression. 
Concentrations of cis-UCA ranging from less than 1 μg to 1 μg to 100 μg were all 
adequate to induce immunosuppression in various experimental models (Ross et al., 
1986; Noonan & De Fabo, 1992; Norval et al., 1989). This suggested that cis-UCA acted 
through a specific receptor mechanism.  
Cis-UCA and Antigen-Presenting Cells  
The immunosuppression induced by cis-UCA also led researchers to hypothesize 
that the signal transduction pathway cis-UCA activates ultimately acts on antigen-
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presenting cells. Because of the role MHC-2 (major histocompatibility complex 2) plays 
in antigen presentation, many studies were conducted to test this association. Noonan et 
al. found that application of cis-UCA to epidermal cells from mice displayed up to a 35% 
decrease in IA (immune-associated, DR) antigen positive, cells (Noonan, De Fabo, & 
Morrison, 1988). Ross et al. similarly found a decrease in IA (immune-associated, DR) 
antigen positive, cells, in murine epidermal cells treated with UV radiation and cis-UCA 
(Ross et al., 1986; Ross et al., 1987). Rasanen et al. further supported these findings by 
showing a reduced count of HLA-DR positive cells in human epidermal cells treated with 
cis-UCA. HLA-DR is the MHC Class 2 cell surface receptor found in humans (Rasanen, 
Jansen, Hyoty, Reunala, & Morrison, 1989). These studies clearly demonstrated the 
ability of cis-UCA to reduce active MHC Class 2 antigen-presenting cells, either through 
a downregulation of expression or a reduction of cell count. Multiple theories arose 
including that cis-UCA causes abnormal migration of antigen-presenting cells from the 
epidermis, that cis-CUA induces abnormal intracellular functioning of antigen-presenting 
cells, including antigen uptake, processing, presentation, and intercellular communication 
(Norval et al., 1989).  
A specific subset of antigen-presenting cells, known as Langerhans cells, were of 
particular interest to researchers due to their location and function in the epidermis. It had 
been shown that UV radiation could result in loss of Langerhans cells in the epidermis 
and an accumulation of dendritic cells in surrounding lymph nodes (Laihia & Jansen, 
1995). It had also been shown that exposure to cis-UCA mimicked these effects, further 
supporting the growing theory that UV radiation acts through cis-UCA in modulating 
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immune function (Laihia & Jansen, 1995). In 1995, Laihia et al. further investigated the 
role that cis-UCA might play in either of these two processes (Laihia & Jansen, 1995). 
They found that treating mice with anti-cis-UCA antibodies prior to UV irradiation 
blocked the loss of Langerhans cells in the epidermis, but did not affect the behavior of 
dendritic cells (Laihia & Jansen, 1995).    
Cis-UCA and Histamine  
Recall that UCA is a derivative of the amino acid histidine. Another derivative of 
histidine is the compound histamine, a regulator of immune function. Histamine, stored 
in secretory granules in mast cells and basophils, activates H1 and H2-receptors. 
Activation of H2-receptors results in immunosuppression, particularly through the action 
of T-suppressor lymphocytes. Norval et. al showed that topical application of histamine 
caused suppression of DTH following infection of HSV, similar to studies using cis-UCA 
(Norval et al., 1989). Structural similarities between the two led researchers to 
hypothesize that cis-UCA may regulate immunosuppression by acting in a similar fashion 
as histamine and by potentially binding to the same H1 and H2-receptors (Norval et al., 
1989). Further research supports the hypothesis that cis-UCA may act similarly to 
histamine; a 1999 study by Wille et al. found that cis-UCA effectively induced release of 
mast cell granules, including mast cell TNF-α (Wille, Kydonieus, & Murphy, 1999). 
Given the complex role that TNF-α plays in modulating immune function, it is highly 
probable that TNF-α could be a downstream effector of the signal transduction pathway 
activated by cis-UCA in immunosuppression.  
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Cis-UCA and DNA Damage  
Due to the growing association between cis-UCA and epidermal malignancy, 
questions arose regarding the potential for UCA to induce DNA damage. Yarosh et al. 
performed a study assaying the ability of UCA, in both isomeric forms, to bind DNA, 
induce DNA mutations, and induce DNA repair (Yarosh et al., 1992). Importantly, 
researchers did not find a conclusive evidence suggesting that cis-UCA or trans-UCA 
interact with DNA in appreciable amounts (Yarosh et al., 1992). This shifted the view of 
the mechanism of action of UCA away from DNA interaction. 
Cis-UCA and UVA versus UVB Radiation  
Most previous research documenting the immunosuppressive properties of cis-
UCA have utilized UVB radiation as the source of radiation exposure. A few studies had 
showed that the physiological behavior of UCA may differ depending on the wavelength 
of UV radiation used. UVA radiation spans wavelengths 320 to 400 nm, compared to 
UVB radiation, which spans wavelengths 280 to 320 nm. In a 1997 by Webber et al., 
researchers found that UVA radiation induced isomerization of trans-UCA to cis-UCA, 
but did not induce immunosuppression (Webber, Whang, & De Fabo, 1997). Thus, this 
suggests that isomerization from the trans to cis form of UCA alone is not sufficient to 
induce isomerization and that other factors are at play. Additionally, it has also been 
shown that isomerization of UCA from trans to cis forms is more sensitive at short UV 
wavelengths, i.e. UVB, compared to, longer wavelengths, i.e. UVA (Webber et al., 
1997). It is likely that of the two main UV wavelengths individuals are exposed to, UVB 
is the more harmful. However, a 1998 study by Hanson et al. showed that mice exposed 
to UVA radiation resulted in higher rates of epidermal photoaging compared to controls 
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(Hanson & Simon, 1998). This suggests that although UVA radiation may not induce 
immunosuppression, it may have other harmful effects that have yet to be discovered.  
 
Figure 4. Different Forms of UV Radiation. There are three forms of UV radiation: 
UVA, UVB, and UVC. UVA ranges from 320-400 nm, UVB ranges from 280-320nm, 
and UVC ranges from about 100-280nm. In general, UVA and UVB irradiation are the 
only two forms that make it past the ozone layer. UVA radiation is more penetrating that 
UVB, reaching the dermis, whereas UVB mainly only penetrates up to the epidermis. 
Taken from Battie & Verschoore, 2012. 
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Cis-UCA and cyclic AMP  
Numerous theories and hypotheses surrounding the mechanism of action of cis-
UCA in the epidermis were being studied during this time period. Another mechanism 
hypothesized that cis-UCA acted at the intracellular level via cyclic AMP. A 1998 study 
by Bouscarel tested the effects of both trans-UCA and cis-UCA on cyclic AMP 
production in three groups of cell lines, human dermal fibroblasts, hamster hepatocytes, 
and a human adenocarcinoma cell line (Bouscarel et al., 1998). They found that neither 
isomer of UCA stimulated synthesis of cyclic AMP in any of the three models (Bouscarel 
et al., 1998). Conversely, they found that cis-UCA alone inhibited synthesis of cyclic 
AMP in the human dermal fibroblast model and that this inhibition was specific to cyclic 
AMP synthesis stimulated by prostaglandins (Bouscarel et al., 1998). Another study by 
Koizumi et al. in 1998 found similar results, showing that cis-UCA inhibited histamine-
induced cyclic AMP synthesis in human keratinocytes (Koizumi, Shimizu, Nishino, & 
Ohkawara, 1998).  
Cis-UCA and Cytokines  
Another component of the signal transduction pathway of cis-UCA lies in 
modulation of cytokine activity. A 1999 study by Krulova et al. illustrated that cis-UCA 
applied topically reduced the likelihood of corneal allograft in a murine model (Krulova, 
Kuffova, Zajicova, Filipec, & Holan, 1999). Through a further in depth in vitro analysis 
of the mechanism behind this graft protection, researchers found that cis-UCA induced 
immunosuppression by activating CD4+ T-lymphocytes and inducing their production of 
IL-10 (Krulova et al., 1999). This seemed to be highly probable as IL-10 is a known 
inhibitor of antigen presentation by APC’s. However, another 1999 study by Bi et al. 
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contradicted these findings as they found that cis-UCA actually inhibited expression and 
subsequent secretion of IL-10 by T-cells (Bi, Xia, & Ni, 1999).  
 
Cis-UCA and an Early Connection to Cancer 
 
Throughout the 1980’s and early 1990’s, the deleterious effects of cis-UCA on 
human health were becoming increasingly evident. While a complete understanding of 
the compound, including its mechanism of action, remained limited, evidence supporting 
its role in immunosuppression was substantial. An important fact to keep in mind is that 
the negative effects of UCA arise from its cis form, rather than from its trans isomer, and 
that UV radiation is the trigger for the isomerization. Marwick raised an interesting 
question, regarding the reason for an evolutionary adaptation behind a pathway that 
suppresses the immune system (Marwick, 1995). When an individual experiences a 
sunburn, components of the “burned” cells appear as foreign invaders to the human 
immune system. Marwick discusses how in order to prevent autoimmune attacks, the UV 
radiation activates UCA from its resting trans isomer to its active cis isomer, which then 
induces immunosuppression to prevent an immune attack against the sunburned 
epidermal cells (Marwick, 1995). Unfortunately, while UCA may have been 
evolutionarily adapted to protect against autoimmune attacks during sunburn, it now also 
has the potential to facilitate immunological evasion by malignant cells created by the 
same UV radiation (Marwick, 1995). UCA has since been removed from cosmetic 
ingredients, especially sunscreens.  
Research regarding the role of cis-UCA in photocarcinogenesis during this time 
period remained relatively limited, yet incredibly informative. As an antigen-presenting 
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cell, Langerhans cells display TAA (tumor-associated antigens) in order to initiate tumor 
immune responses. In a 1997 by Beissert et al., researchers investigated the role that 
UCA, either trans-UCA or cis-UCA, play in modulating TAA presentation by 
Langerhans cells (Beissert et al., 1997). Using a CAF1 murine model immunized against 
the S1509 spindle cell tumor line, they found that only cis-UCA, not trans-UCA, 
inhibited antigen presentation activity of epidermal Langerhans cells (Beissert et al., 
1997). They also found that only cis-UCA, not trans-UCA, inhibited a delayed-type 
hypersensitivity response upon antigen exposure (Beissert et al., 1997). Studies of cis-
UCA and photocarcinogenesis have also been conducted in human models. In 1998, De 
Fine et al. measured levels of cis-UCA in patients with skin cancer, patients with 
previous history of skin cancer, and healthy controls (De Fine et al, 1998). Baseline 
levels of cis-UCA did not differ significantly between the two groups, however, levels of 
cis-UCA following a single dose of UV radiation were higher in groups who had skin 
cancer or previous history of skin cancer, compared to healthy controls (De Fine et al, 
1998). This suggests a possibility that individuals suffering from epidermal malignancies 
experiencing pathological changes that influence current and future exposure to added 
UV radiation.  
In a study by Snellman et al. in 1999, researchers found that there was no 
significant difference in total UCA and trans-UCA levels in groups of cutaneous 
malignant melanoma, basal cell carcinoma, and controls (Snellman, Jansen, Rantanen, & 
Pasanen, 1999). Importantly, trans- to cis-UCA isomerization induced by one dose of UV 
radiation was lower in skin cancer patients, compared to controls (Snellman et al., 1999). 
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This further suggests that epidermal responses to future doses of UV radiation are altered 
in individuals with pathological changes to the skin, including malignant 
transformations.   
Where does UCA stand at the turn of the 20th century? 
 
During the end of the 1990’s and the approach of the 21st centuries, a few studies 
were published that presented alternative viewpoints to the current understanding of 
UCA. Whereas cis-UCA clearly posed negative effects on epidermal health due to its 
immunosuppressive properties, the idea of trans-UCA acting as a natural sunscreen still 
remained. A study done by De Fine et al. in 1996 investigated the photoprotective 
properties of trans-UCA (De Fine, Wulf, Crosby, & Norval, 1996). They found that 
topical application of 5% trans-UCA provided a 1.58 sun protection factor in 36 healthy 
human subjects (De Fine et al., 1996). The authors noted, however, that because the 
concentration of topical trans-UCA applied was higher than physiological levels of 
epidermal trans-UCA by about 20-200, it would be unlikely that the main purpose of 
physiological trans-UCA be based in photoprotection (De Fine et al., 1996). The 
following year, De Fine et al. continued their research in identifying an endogenous role 
for UCA and investigated concentrations of UCA in various areas of the epidermis (De 
Fine et al., 1997). In a study of 36 healthy participants, they found that the percentage of 
cis-UCA was the highest in body regions exposed to UV radiation (De Fine et al., 1997). 
These findings suggest that the role of UCA remains in the realm of photobiology and 
photoprotection, slightly contrasting with their previous work.  
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A complete understanding of UCA has yet to be established. As shown here and 
in previous sections of this paper, scientific understanding regarding UCA has grown 
immensely but remains limited and inconclusive. Bits and pieces of valuable information 
regarding UCA has been elucidated, but the entire story behind UCA is still relatively 
fragmented. Still, in recent years, research around UCA and its role in epidermal health 
has rapidly resurfaced. For instance, a study by De Fine et al. in 1999 illustrated the 
differential immunosuppressive effects in individuals of varying pigmentation levels (De 
Fine, Wulf, Crosby, & Norval, 1996). In a study of 28 health subjects, they found higher 
rates of trans- to cis-UCA isomerization in lighter pigmented versus heavier pigmented 
individuals, suggesting than lighter pigmented individuals have higher 
immunosuppressive risk upon UV exposure (De Fine et al., 1996). This suggests 
potential interplay between cis-UCA and melanin, a plausible hypothesis given the 
proximity of the two compounds within the epidermis. Numerous more studies such as 
these have shown promise in completing our understanding of UCA and have continued 
well into the 21st century. The following section provides an in-depth analysis of 
research conducted on UCA after the year 2000, specifically focusing on the connection 
between UCA and epidermal malignant transformations.  
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ADVANCEMENTS IN UROCANIC ACID RESEARCH (Post-21st Century)  
 
Molecular Understanding of Urocanic Acid 
 
UCA is Derived from Filaggrin  
Although current studies have shown that external additions of UCA have 
induced immunosuppression through the action of cis-UCA, the normative function of 
baseline physiological UCA levels remains yet to be discovered. Recall that histidine is 
the precursor to UCA, converted through the action of the enzyme, histidase. Due to high 
levels of histidine present in the filaggrin protein in the epidermis, researchers have 
hypothesized that filaggrin proteins are the original source of histidine used to produce 
UCA in the stratum corneum (Mildner et al., 2010). In a 2010 study by Mildner et al., 
investigators found that in vitro filaggrin knockout models showed a drop in UCA 
concentration by over half, when compared to baseline controls (Mildner et al., 2010). 
Despite the association of cis-UCA with induction of immunosuppression, trans-UCA 
still remains a potent protector against UV irradiation. Thus, reduced levels of total UCA 
in filaggrin knockout model resulted in reduced levels of trans-UCA and increased UVB-
induced damage, including formation of pyrimidine dimers and activation of apoptotic 
caspase pathways (Mildner et al., 2010).  
A recent 2017 study by Simonsen et al. supports these findings, by showing that 
individuals irradiated with minimal doses of UVB radiation displayed reduced levels of 
filaggrin protein, in addition to reduced levels of trans-UCA (Simonsen, Thyssen, 
Heegaard, Kesiz, & Skov, 2017). Interestingly, UV irradiation has been repeatedly shown 
to induce isomerization of trans- to cis-UCA, but these results now also suggest that UVB 
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irradiation reduces total levels of UCA by modulating filaggrin levels (Simonsen et al., 
2017). It is possible that this serves as an evolutionary adaptation to cap the total level of 
cis-UCA that can be formed in response to UVB irradiation.  
UCA Activation Independent of Method of Irradiation  
In the previous studies of UCA analyzed pre-21st century, recall it was noted that 
the wavelength most effective in inducing trans- to cis-UCA photoisomerization was 
UVB, in the 240 to 270 nm range. In recent years, further research has expanded on these 
findings and discovered that not only is UCA photoisomerization dependent on the 
wavelength, but it is also dependent on the route of irradiation delivery (Brookman, 
Chaco, & Sinclair, 2002). A 2002 study by Brookman et al. tested the behavior of both 
trans-UCA and cis-UCA when using pulsed UV irradiation methods (Brookman, 2002). 
They found that percentage photoisomerization yielded upon pulsed UV irradiation at 
266 nm was similar to percentage photoisomerization yielded with standard methods of 
UV irradiation (Brookman, 2002). 
UCA Activation Dependent on Wavelength and Microenvironment  
While the percentage photoisomerization of trans- to cis-UCA has not been 
shown to differ depending on route of continuous or pulsed UV irradiation, evidence has 
previously showed that it does depend on wavelength range (Webber et al., 1997). Recent 
research has also suggested that the photoisomerization of UCA depends on the makeup 
of its microenvironment. A 2004 study by Wallis et al. has shown that in nonaqueous 
solvents, rates of trans- to cis-UCA photoisomerization correlates linearly with degree of 
solvent polarity (Wallis, Smith, & Dunford, 2004). This has important implications for 
production of any potential future compound containing UCA, particularly those that aim 
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to isolate trans-UCA for its natural sunscreening properties. Topical formulations that 
alter the microenvironment of the stratum corneum, specifically those that shift the 
microenvironment towards increasing polarity, may result in increased 
photoisomerization of UCA and subsequent immunosuppression (Wallis et al., 2004).  
Cis-UCA Induction of Immunosuppression in Human Models  
While the evidence surrounding cis-UCA and induction of immunosuppression 
has gained a sizeable foundation of knowledge in the past fifty years, studies in humans 
have been relatively limited. Studies that have been conducted in humans seem to 
corroborate findings concluded from in vitro and in vivo animal models. A study by Dahl 
et al. in 2010 found that roughly one-third of patients treated with topical cis-UCA 
experienced immunosuppression when challenged by DNCB (Dahl, McEwen, & Katz, 
2010). 
Cis-UCA Effects on Immune Cells  
The ability of cis-UCA to induce systemic immunosuppression has been well-
documented, particularly through studies showing prevention of allograft rejection and 
reduced CHS and DTH responses using extended doses of cis-UCA. What has been less 
studied are acute exposures to cis-UCA and their effects on specific populations of T-
lymphocytes, a question investigated by Prater et al. in 2003. They observed 
immunological changes following one day, five days, and 30 day doses of cis-UCA in a 
C56BL/6N murine model (Prater, Gogal, De Fabo, Longstreth, & Holladay, 2003). 
Single day doses of cis-UCA resulted in reduced ability of splenocytes to undergo 
phagocytosis, five-day doses of cis-UCA resulted in reduced cell counts of mature CD4+ 
and CD8+ thymocytes and increased cell counts of immature CD4+ CD8+ thymocytes, 
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and thirty-day doses resulted in reduced total cell counts in the thymus and increased total 
cell counts in the spleen (Prater et al., 2003b).  
In addition to regulation of T-lymphocytes, cis-UCA has continually been shown 
to modulate the function of Langerhans cells, a key immune cell located in the epidermis 
(Beissert et al., 2001). However, what has been recently shown is that trans-UCA may 
also be implicated in modulating immune function. A 2016 study by Bruhs showed that 
non-irradiated mice deficient in histidine displayed stronger immune reactions when 
challenged with a TNCB sensitizer (Bruhs, Eckhart, Tschachler, Schwarz, & Schwarz, 
2016). Because these were non-irradiated mice, the bulk isomer of UCA remained in the 
trans form, indicating that trans-UCA may also play a role in modulating Langerhans 
cells of the epidermis (Bruhs et al., 2016). 
Cis-UCA and the 5-HT2A Receptor  
The 5-HT2A Receptor is a G-protein Coupled Receptor (GPCR) that binds the 
ligand, serotonin, and has been implicated in many physiological processes, including 
neurological functioning, smooth muscle contraction, endocrine functioning, so on and so 
forth. The link between activation of cis-UCA in the epidermis and the downstream 
suppression of the immune system remains relatively elusive to this day. New research 
has hypothesized that cis-UCA acts through the 5-HT2A Receptor to induce systemic 
immunosuppression (Walterscheid et al., 2006). A 2006 study by Walterscheid et al. has 
shown that cis-UCA binds 5-HT receptors with high affinity and that both anti-cis-UCA 
antibodies bind 5-HT and anti-5-HT antibodies bind cis-UCA (Walterscheid et al., 2006). 
Additionally, they found that both 5-HT2A receptor antagonists and anti-serotonin 
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antibodies were capable of inhibiting immunosuppression in vitro, induced by either UV 
irradiation or application of cis-UCA (Walterscheid et al., 2006).  
Cis-UCA as Modulator of Cytokine Expression 
The theory of cis-UCA as a regulator of gene expression, particularly for 
immunomodulatory intermediates, has grown in popularity in recent years. A 2008 study 
by Kaneko investigated the effect of cis-UCA on expression of immunomodulatory 
cytokines using a microarray analysis of human keratinocytes (Kaneko et al., 2008). They 
found that cis-UCA was responsible for the upregulation of 16 total genes, whose 
functions were associated with apoptosis, arrest of cell growth, stress pathways, and 
cytokine production (Kaneko et al., 2008). More specifically, they found that cis-UCA 
was responsible for increasing the synthesis of PGE2 and cytokines: TNF-α, IL-6, and 
IL-8. Synthesis of these intermediates correlated linearly with cis-UCA dosages (Kaneko 
et al., 2008). None of these effects were observed with application of trans-UCA (Kaneko 
et al., 2008).   
Opposition Against UCA as an Inducer of Immunosuppressive Cytokines  
Recall that in a select few studies analyzed prior to the turn of the 21st century, 
researchers showed evidence showing that UCA, specifically cis-UCA, acts an as 
inductor of immunosuppression by inducing the production of immunosuppressive 
cytokines. Moving into the 21st century, a few more studies have surfaced showing 
evidence to oppose this mechanism of action. In a 2001 study by Zak et al., researchers 
tested the ability of cis-UCA to induce release of immunosuppressive cytokines in a 
PAM-212 murine keratinocyte cell line (Zak et al., 2001). They found no significant 
changes in expression of key immunosuppressive cytokines, including IL-10, TGF-β, and 
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TNF-α (Zak et al., 2001). Thus, this study suggests that induction of expression of 
immunosuppressive cytokines may not be the mechanism by which cis-UCA exerts its 
influences on the immune system. These results were supported by another 2001 study 
performed by Amerio, where researchers conducted a CHS assay on TNF-α receptor 
knockout mice, treated with UV irradiation or intradermal injection with UCA (Amerio et 
al., 2001). They found that both local and systemic immunosuppression was still 
observed in TNF-α receptor knockout mice following either UV irradiation or 
intradermal cis-UCA injection, indicating that TNF-α activation may not be not required 
for induction of immunosuppression by cis-UCA (Amerio et al., 2001). However, it is 
important to recognize that these are the results of a small sample size of studies and 
further studies should be done to confirm the preciseness and accurateness of these 
conclusions.  
Cis-UCA and Permethrin  
Permethrin is an insecticide commonly used topically to treat conditions such as 
scabies and lice. Permethrin is also a known inhibitor of CHS; given these 
immunosuppressive properties, researchers have hypothesized connections between 
permethrin and cis-UCA (Prater, Blaylock, & Holladay, 2003). A 2003 study was 
conducted by Prater et al. investigation levels of CHS inhibition mice treated with 
intradermal cis-UCA, topical permethrin, or both intradermal cis-UCA and topical 
permethrin (Prater et al., 2003a). They found that independent application of either 
intradermal cis-UCA or topical permethrin resulted in inhibition of CHS, with application 
of both chemicals resulting in an even greater inhibition of CHS (Prater et al., 2003a). 
Moreover, it was found that TNF-α receptor knockout mice experienced only partial 
 30 
abrogation of inhibition of CHS when given either of the three treatment method (Prater 
et al., 2003a). It was also found that INF-y receptor knockout mice experienced partially 
abrogated inhibition of CHS only when given either cis-UCA or permethrin alone (Prater 
et al., 2003a). This abrogation was not observed with combined cis-UCA and permethrin 
in IFN-γ knockout mice (Prater et al., 2003a). These findings suggest that TNF-α and 
INF-y are not necessarily required in the signal transduction cascade initiated by cis-
UCA, but are likely still involved in the pathway. This also suggests that IFN-γ may play 
a bigger role in inhibition of CHS response when induced by both cis-UCA and 
permethrin.   
UCA and Acidification  
Up until the turn of the 21st century, the main understanding of UCA’s function 
within the epidermis has focused on trans-UCA as a potential natural sunscreen and cis-
UCA as a regulator of UV-induced immunosuppression. Recent studies have shown that 
the function of UCA within the epidermis may be broader than originally theorized. A 
study by Krien et al. in 2000 suggested that UCA may play important roles in the 
differentiation of the stratum granulosum to the stratum corneum layer and in regulation 
of enzymatic processes within the stratum corneum (Krien & Kermici, 2000). By 
analyzing the proton flux via electrode of forearm skin in 12 healthy subjects, they found 
that the pH of the of the stratum corneum correlated with levels of UCA (Krien & 
Kermici, 2000). In regards to enzymatic processes, this suggests that UCA likely 
contributes to the acidic microenvironment of the stratum corneum. Furthermore, because 
of the pH-dependent activation of the histidase enzyme, researchers concluded that the 
 31 
production of UCA in the stratum corneum is potentially a self-regulated process (Krien 
& Kermici, 2000).  
Importantly, a conclusive understanding of UCA’s role in acidification of the 
stratum corneum remains fragmented. Still, other studies have shown that UCA is 
unnecessary for the acidification of the stratum corneum. Rather, these findings assert 
that sPLA2 and NHE1 are the mediators responsible for modulating the pH stratum 
corneum (Fluhr et al., 2010). They show that abrogation of sPLA2 and NHE1 pathways 
reduces acidification of the stratum corneum with resultant increases in pH (Fluhr et al., 
2010). 
Current Roles in Epithelial Health 
  
Physiological Role of Endogenous UCA  
While the effects of excess UCA applied to both in vitro and in vivo biological 
systems have been the focus on most UCA studies throughout the past fifty years, the 
normal, physiological role of UCA has remained rather elusive. Speculation that UCA 
functions as an endogenous photoprotectant still remains, a theory further studied by 
Barresi et al. in 2011. These investigators utilized histidase-deficient mice to study the 
role of UCA in a murine model (Barresi et al., 2011). Mice lacking histidase, and thus 
lacking UCA, were observed to have higher levels of pyrimidine dimer formations and 
apoptotic cell death activity, where treatment with topical UCA to mice lacking histidase 
reversed these effects (Barresi et al., 2011). 
Cis-UCA and Phototherapy  
Phototherapy, also referred to as light therapy, consists of regulated forms of 
exposure to specific wavelengths of light to prevent, treat, and manage certain disease 
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pathologies, particularly those related to dermatological function. Despite the negative 
reputation cis-UCA has earned in regards to its immunosuppressive properties, UCA has 
been hypothesized to serve important roles in the physiological effects associated with 
phototherapy (Beissert & Schwarz, 2002). We have already seen that cis-UCA is capable 
of suppressing immune reactions to sensitizer agents, including suppression of CHS and 
DTH. The ability of cis-UCA to participate in phototherapeutic pathways has been 
attributed to the likelihood that it reduces inflammation (Beissert & Schwarz, 2002). 
 
 
Table 2. Indications for Phototherapy. A specific form of phototherapy is UV 
phototherapy, which utilizes various wavelengths within the UV spectrum to treat 
diseases, particularly dermatologic conditions. There are three main types of UV 
phototherapy: narrowband UVB, psoralen and UVA, and UVA1. Taken from Totonchy 
& Chiu, 2014.   
 
Ocular Epithelial Health  
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Though immunosuppression is deleteriously associated with certain disease 
pathologies, such as malignant transformation, it can have potently beneficial effects on 
treatment and management of other conditions that require inflammation reduction. Some 
ocular conditions serve as prime examples, including uveitis, blepharitis, and keratitis. 
Inflammation associated with these conditions is not only potentially damaging to ocular 
function, but results in extreme pain and uncomfortability for patients. A 2009 study by 
Viiri et al. illustrated that cis-UCA may serve as a promising therapeutic agent against 
inflammation in human ocular cells, specifically corneal and conjunctival cells (Viiri et 
al., 2009). They found that application of cis-UCA to an in vitro assay of these cell 
populations abrogated the pro-inflammatory effects associated with UVB irradiation and 
resulted in decreased secretion of IL-6, IL-8, and reduced apoptotic caspase pathways 
(Viiri et al., 2009). 
In addition to inhibiting secretion of pro-inflammatory mediators in ocular cells, 
cis-UCA has also been shown to block ocular inflammation through inhibition of the 
SAPK/JNK pathway (Jauhonen et al., 2011). Normally, part of the pro-inflammatory 
pathway induced by UVB irradiation on ocular cells facilitates increased expression of c-
Jun, c-Fos, and NF-KB (Jauhonen et al., 2011). In a 2011 study by Jauhonen et al., 
researchers found that an in vitro application of cis-UCA inhibited binding of 
transcription factors and reduced gene expression of c-Jun and c-Fos in human corneal 
cells, not NF-KB (Jauhonen et al., 2011). Because of the anti-inflammatory effects of cis-
UCA in response to UVB irradiation, researchers speculate it has high potential to 
become a potent therapeutic to control inflammation within this organ system (Jauhonen 
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et al., 2011). Importantly, these results differ from the effects of cis-UCA often observed 
in the epidermis. Thus, it is important to recognize that the effects of cis-UCA may vary 
across organ systems and this should be taken into consideration when developing new 
therapeutics. 
UCA and Cancer  
While cis-UCA has been traditionally associated with UV-induced 
immunosuppression that has deleterious associations with malignant epidermal 
transformations, researchers have unveiled an anti-proliferative effect associated between 
cis-UCA and bladder cancer (Arentsen et al., 2012). Application of cis-UCA in a rat 
bladder cancer cell line and a murine bladder cancer model showed reduction of cellular 
proliferation in the cell lines and reduction of tumor growth in the in vivo tumor model 
(Arentsen et al., 2012). This application was specific to non-muscle invasive bladder 
cancer with cis-UCA delivered through intravesicular agents (Arentsen et al., 2012). 
Thus, cis-UCA may not be a viable treatment option for muscle invasive bladder cancers.  
In addition to potential as a therapeutic for bladder cancer, UCA has also shown 
promise as a treatment for lung cancer as well. This has been combined with a relatively 
new form of therapeutic delivery, aerosol delivery, due to its less invasive and non-viral 
based delivery system. A 2006 study by Jin et al. utilized a novel urocanic-acid-modified 
chitosan (UAC) treatment method delivered through aerosol gene delivery to a lung 
cancer murine model (Jin et al., 2006). The urocanic acid-based delivery method is used 
to deliver the PDCD4 gene to cancer cells in mice lungs (Jin et al., 2006).  Because of the 
ability of PDCD4 overexpression to activate apoptotic cellular pathways in other forms of 
cancer, including breast cancer, it was employed to test its ability to activate apoptotic 
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pathways in lung cancer cells (Jin et al., 2006). It was found that mice treated with the 
UAC-method carrying the PDCD4 gene displayed higher rates of cancer cell apoptosis, 
reduced rates of cellular growth, and inhibits angiogenesis (Jin et al., 2006). 
UCA and Skin Conditions 
Oedema and Erythema  
Oedema and erythema are both forms of epidermal inflammation. Due to the 
immunosuppressive properties of cis-UCA, studies have been conducted investigating the 
potential of UCA to act as an anti-inflammatory therapeutic agent. In a 2012 study by 
Laihia et al., researchers found that topical application to cis-UCA to murine models with 
epidermal inflammation showed reduced signs of inflammation by the end of the 
treatment period (Laihia, Taimen, Kujari & Leino, 2012). Importantly, results showed 
cis-UCA displayed stronger acute anti-inflammatory properties compared to standard 
anti-inflammatory treatment agents, including hydrocortisone (Laihia et al., 2012). If 
formulated safely and effectively, cis-UCA may serve as a potent target for treating 
inflammatory skin conditions.  
Atopic Dermatitis  
Atopic dermatitis, also referred to as eczema, is an inflammatory skin condition 
that causes skin to become itchy, red, swollen, dry, so on and so forth. The current 
understanding of cis-UCA as an immunosuppressor has led to many studies being 
conducted regarding therapeutic potential of cis-UCA in treating pro-inflammatory 
conditions. In phase 1 and 2 double-blinded randomized control clinical trials conducted 
by Peltonen et al. in 2014, the therapeutic safety and efficacy of topical application of cis-
UCA was tested in 16 subjects (Peltonen et al., 2014). Results showed reduced 
inflammation in groups receiving the cis-UCA treatment, compared to groups receiving 
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placebo. Furthermore, no toxicity was observed and the treatment itself was tolerated 
well by the subjects receiving it (Peltonen et al., 2014). 
Chronic Spontaneous Urticaria  
Chronic Spontaneous Urticaria is an inflammatory skin condition associated with 
hives and often angioedema. Because previous research has shown that high levels of 
filaggrin protein have been associated with increased severity of CSU, studies have been 
conducted investigating the role that cis-UCA, a derivative of filaggrin, may play in 
disease progression (Pham et al., 2017). It was found that cis-UCA was able to increase 
degranulation of basophils and mast cells, which is hypothesized to contribute to the pro-
inflammatory symptoms of CSU (Pham et al., 2017). It was also found that CSU patients 
possessed higher levels of cis-UCA compared to trans-UCA, indicating that the high 
levels of cis-UCA may be responsible for symptoms such as the redness and itching of 
hives (Pham et al., 2017). Targeting cis-UCA to reduce its epidermal levels may serve as 
a potential therapeutic pathway for treating CSU.  
UCA and Vitamin D  
Due to the dependence of Vitamin D production on UVB radiation from sunlight, 
considerable interest has arisen concerning the potential interplay between cis-UCA and 
Vitamin D synthesis in the epidermis. A 2016 study by Landeck et al. found that a sample 
of 28 contact dermatitis patients treated with sub-erythemal UVB irradiation displayed 
the expected conversion of trans- to cis-UCA in addition to increased 25-hydroxyvitamin 
D levels (Landeck et al., 2016). The levels of vitamin D were shown to be inversely 
proportional to levels of trans-UCA, as expected (Landeck et al., 2016). 
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UCA and Autoimmune Encephalomyelitis  
Autoimmune encephalomyelitis encompasses a wide variety of diseases that 
involve immune attack against neurological cells. It has been shown that UVB irradiation 
protects against experimentally-induced autoimmune encephalomyelitis, prompting 
researchers to speculate whether the immunosuppressive properties of cis-UCA are 
involved in this process. In a recent 2017 study by Irving et al., researchers tested 
protection against experimentally-induced autoimmune encephalomyelitis using UVB 
irradiation, both isomeric forms of UCA, and a control treatment (Irving, Marling, Plum, 
& DeLuca, 2017). They found that UVB irradiation protected against disease progression 
by nearly 80%, where cis-UCA levels were prominent (Irving et al., 2017). However, 
increasing cis-UCA levels further did not confer any additional protection, suggesting 
that other mechanisms induced by UVB irradiation are responsible for protection against 
experimentally-induced autoimmune encephalomyelitis (Irving et al., 2017). 
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DISCUSSION OF THERAPEUTIC APPLICATIONS 
 
Potential Role as Therapeutic Target for Skin Cancer 
 
UCA as a Measure of Commercial Sunscreen Efficacy  
From SPF (sun protection factor) 15 to SPF 100, sunscreen has served as one of 
the main methods of risk reduction and prevention of skin cancer for generations. Though 
most current studies discussing the potential roles of UCA as a therapeutic target for skin 
cancer have focused on molecular mechanisms, one study provided a novel suggestion to 
use UCA as a marker for current commercial sunscreen efficacy (Van Der Molen et al., 
2000). Using both in vivo models of healthy human volunteers and ex vivo models of 
human skin, researchers determined that effectiveness of sunscreens measured by sun 
protection factor correlated with percentage protection against photoisomerization from 
trans-UCA to cis-UCA (Van Der Molen et al., 2000). In addition, they found that broad-
spectrum sunscreens provided greater protection against UCA photoisomerization, 
indicating that sunscreen UV absorption spectrums may be of greater priority compared 
to penetration characteristics (Van Der Molen et al., 2000). 
 A 2005 study by McLoone et al. have also corroborated this theory by 
investigating the rates of trans- to cis-UCA photoisomerization in five healthy human 
subjects (McLoone et al., 2005). They found that maximal production of cis-UCA from 
the trans isomer occurred in the UVB range of 280 to 310 nm (McLoone et al., 2005). 
This encompasses a UV spectrum wider than those currently specified for protection 
against UV-induced erythema. Speculation has grown in recent years surrounding a gap 
between the ability of commercial sunscreens to protect against UV-induced erythema 
and UV-induced immunosuppression. The requirement of a broad spectrum formulation 
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to reduce UCA photoisomerization may serve as the solution for that gap (McLoone et 
al., 2005).  
A decade into the new century, research has expanded on the initial idea of using 
cis-UCA as a measure for the effectiveness of commercial sunscreens. Recently, research 
has focused on employing non-invasive means of measuring UCA levels through Raman 
spectroscopy as, which is both time and cost efficient for researchers but more 
importantly, safe and effective for study participants. A 2008 study by Egawa et al. found 
that confocal Raman spectroscopy effectively measured the levels of UCA, especially 
trans-UCA in this study, in an in vivo model of about 20 subjects (Egawa & Iwaki, 2008). 
Importantly, application of sunscreen decreased the effects of UV radiation on trans-UCA 
levels, and this was accurately captured by the Raman spectroscopy method (Egawa & 
Iwaki, 2008). A few years later, Egawa et al. expanded on these findings and tested the 
ability of the Raman spectroscopy to measure both cis-UCA and trans-UCA levels 
specifically within the stratum corneum, validated using stratum corneum paper strip 
samples (Egawa, Nomura, & Iwaki, 2008). The rose in levels of cis-UCA and fall in 
trans-UCA levels following UV irradiation were correctly measured by Raman 
spectroscopy (Egawa et al., 2008).  
Use of IL-12 to Modulate cis-UCA  
While trans-UCA has been relatively well-established as a protective mediator 
against the effects of UV irradiation, cis-UCA has been implicated in UV-induced 
immunosuppression associated with enabling malignant evasion of the immune system. 
One potential target to prevent this evasion is targeting the cytokine IL-12, an 
immunological mediator with anti-immunosuppressive properties, as an indirect means of 
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targeting cis-UCA (Beissert et al., 2001). A 2001 study by Beissert et al. investigated the 
ability of IL-12 to inhibit the immunosuppressive properties of cis-UC in both in vitro 
and in vivo models (Beissert et al., 2001). They found that application of IL-12 was 
capable of suppressing immunosuppression induced by cis-UCA in vitro in Langerhans 
Cells, enabling the LCs to regain function of antigen-presentation (Beissert et al., 2001). 
They also found that application of anti-cis-UCA antibodies to mice with skin cancer 
reduced tumor yield in this in vivo murine model, indicating that inhibition of cis-UCA 
may serve as a potent target for preventing, treating, and managing carcinoma induced by 
UV irradiation (Beissert et al., 2001).   
 
UCA and Reactive Oxygen Species  
Recognition of the beneficial effects of trans-UCA as a protectant against the 
effects of UV irradiation has led to research focused on isolating this isomer and ensuring 
maintenance of the trans form once it has reached the epidermis. Reactive oxygen species 
(ROS) are highly reactive compounds derived from molecular oxygen (O2) that are 
associated with a number of deleterious effects, from the cellular level in induction of 
oxidative damage and stress to pathological levels with neurocognitive decline and 
cancer progression. Recent research has provided evidence suggesting trans-UCA is 
capable of quenching reactive oxygen species produced by UV irradiation. A 2002 study 
by Haralampus-Grynaviski et al. confirmed the production of reaction oxygen species by 
UVA irradiation in a cholesterol hydroperoxide assay followed by quenching of these 
reactive oxygen species by application of trans-UCA (Haralampus-Grynaviski et al., 
2002). A later 2011 study by Tiwari et al. also concluded that UCA could serve as a 
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hydroxyl radical scavenger, contributing to the theory that UCA acts as a physiological 
antioxidant (Tiwari & Chand Mishra, 2011).   
The development of a trans-UCA therapeutic is challenging, particularly because 
of the importance of maintaining UCA in the trans form and preventing 
photoisomerization to the cis form. Interestingly, whereas we had seen above that trans-
UCA was implicated in quenching of reactive oxygen species, the cis form of UCA has 
been shown to contribute to formation of reaction species under UV irradiation (Menon 
& Morrison, 2002). A 2002 study by Menon et al. illustrated that cis-UCA was capable of 
inducing the development singlet reactive oxygen species following UCA irradiation 
(Menon & Morrison, 2002). A later 2011 study by Kaneko et al reported that cis-UCA 
was capable of generating reactive oxygen species in a human keratinocyte cell line, 
which was associated with the ability of cis-UCA to increase prostaglandin production 
and promote cell apoptosis (Kaneko et al., 2011).  
UCA and DNA Photoproducts  
DNA damage, particularly the production of DNA photoproducts including 
pyrimidine dimers, plays a primary role in cancerous transformations within the 
epidermis. For the most part, the two processes induced by UV irradiation that have been 
linked to cancer progression, DNA damage with photoproduct production and 
immunosuppression induced by cis-UCA have remained relatively independent of one 
another. Recent research has suggested that a link may exist between these two processes 
(Snellman, Xu, Pasanen, Laihia, & Hemminki, 2002). If this is the case, individuals with 
high concentrations of epidermal cis-UCA combined with defective DNA repair 
mechanisms would suffer from an even greater risk of UV-induced skin cancer compared 
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to possessing either risk factor alone. Although data on this process remains somewhat 
limited, a 2002 study by Snellman et al. found that a few potential links between 
processes involving DNA photoproducts, including DNA photoproduct repair 
mechanisms, and concentration of cis-UCA within the epidermis (Snellman et al., 2002).  
UCA and Tumor Growth  
While most research has supported the link between cis-UCA and progression of 
tumor growth, a few, select studies have shown otherwise. In a 2002 study, Macve & 
Norval found that injection fibrosarcoma (FS) cells into a murine model irradiated with 
UVA radiation resulted in proliferation of tumor cells, compared to non-irradiated 
controls (Macve & Norval, 2002). Importantly, these observations were not replicated 
when cis-UCA was applied topically of injected intradermally in place of UVA 
irradiation, suggesting that cis-UCA is not the mediator by which UV radiation induces 
tumor cell proliferation (Macve & Norval, 2002). Additionally, it was found that 
application of anti-cis-UCA antibodies did not reverse the effects originally seen in mice 
irradiated with UVA radiation, further suggesting other pathways are responsible for 
tumor growth upon exposure to UV radiation (Macve & Norval, 2002).   
UCA as a Biomarker  
The relative physiological increase of UCA, particularly total UCA and cis-UCA 
content, following exposure to UV irradiation has led to speculation regarding the use of 
cis-UCA as a biomarker for UV exposure. A 2005 study by Sastry et al. found that 
minimal erythemal doses of UV radiation resulted in nearly five-fold increase in UCA 
biomarker, measured using HPLC (high-performance liquid chromatography) analysis of 
human urine samples (Sastry et al., 2005). The UCA biomarkers was defined as a UCA 
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ratio, a ratio of cis-UCA to trans-UCA, or as the amount of cis-UCA corrected for urine 
volume (Sastry et al., 2005).  
Because of the damaging effects of cis-UCA on the immune system and its 
association with cancerous progression in the epidermis, levels of cis-UCA can also 
potentially serve as a useful biomarker when monitoring the safety of UV-associated 
activities. Excessive overexposure to sunlight has long been established as a risk factor 
for developing skin cancer, but use of artificial UV exposure such as through commercial 
suntanning has been posed as an even greater risk factor. Despite warnings regarding this 
activity, commercial suntanning remains an activity highly engaged in by the public. Part 
of this may stem from a lack of a direct biomarker linked to increased risk of skin cancer 
in that can be measured in individuals who engage in commercial suntanning. In a 2002 
study by Ruegemer et al., researchers found that total UCA and cis-UCA content 
increased in UV-exposed skin, even prior to any clinically observable effects including 
changes in skin pigmentation and observed sunburn (Ruegemer et al., 2002).  
Antigen Viability Facilitates Direction of UCA as Therapeutic Target  
As mentioned previously, exposure to UV radiation causes the activation of two 
different pathways associated with cancer pathogenesis: DNA damage with photoproduct 
development and activation of cis-UCA and immunosuppression. Recent research has 
shown that the viability of the antigen may determine which of these pathways dominates 
and thus will direct treatment strategies used to prevent or treat cancerous transformations 
(Kim et al., 2003). A novel study by Kim et al. in 2003 applied either anti-cis-UCA 
antibodies or endonucleases to a murine model to identify which of these treatments 
would induce immunosuppression of DTH (Kim et al., 2003). If mice treated with anti-
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cis-UCA antibodies displayed abrogation of DTH suppression, it would indicate that the 
cis-UCA pathway was dominant. Conversely, if application of endonucleases resulted in 
blocking DTH suppression, one could reasonably conclude that the DNA damage-
associated pathway was dominant. Researchers found that anti-cis-UCA antibodies were 
only capable of abrogating DTH suppression when live antigen sensitizers were used to 
induce DTH (Kim et al., 2003). Conversely, it was found that endonucleases were only 
capable of blocking DTH suppression when non-live antigen sensitizers were used to 
induce DTH (Kim et al., 2003). Thus, when designing therapeutics to inhibit 
immunosuppression, whether in the context of cancer or other conditions, properties of 
the antigen need to be taken into consideration for the treatment to be effective.  
The Return of the 5-HT2 Receptors 
In the previous section analyzing post-2000 early research regarding the role of 
UCA in both physiological and pathological pathways, some studies suggested that cis-
UCA was capable of binding to 5-HT2A receptors and potentially served as an important 
focal point of the cis-UCA immunosuppression signal transduction cascade. Modern day 
research has expanded on these findings, which has not only confirmed that cis-UCA is 
capable of binding serotonin receptors, but that this binding is responsible for cis-UCA-
mediated immunosuppression and that blocking this binding could abrogate inhibition of 
the immune response (Ulrich, 2007). In a 200 7 paper by Ulrich, researchers found that 
use of a selective serotonin receptor antagonist, originally to be used as a control 
measure, was able to inhibit the immunosuppressive properties of cis-UCA (Ulrich, 
2007). To further investigate upon this finding, they found that application of excess 
amounts of cis-UCA was able to displace bound cis-UCA or bound 5-HT to human 
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serotonin receptors, whereas 5-HT receptor antagonists were able to inhibit this binding 
entirely (Ulrich, 2007).  
These findings were also supported in a 2010 study by Sreevidya et al., where 
serotonin receptor antagonists were shown to reduce UV-induced immunosuppression 
and UV-induced carcinogenesis, in addition to promoting DNA repair (Sreevidya et al., 
2010). Furthermore, researchers found that the ability of serotonin receptor antagonists to 
promote DNA repair was blocked when applied to mice deficient in DNA repair 
enzymes, indicating that serotonin receptor antagonists interact with DNA repair 
mechanisms (Sreevidya et al., 2010).   
UCA Mimic  
Although the normal form of cis-UCA has been generally shown to have 
deleterious effects within the epidermis and systemically in regards to the immune 
system, researchers have begun testing the possibility of modifying UCA into a form with 
only beneficial effects. In a recent 2015 study, Ito et al. prepared urocanic acid-based 
chitin nanofibers and found that application of these UCA nanofibers protected against 
sunburn in a murine model (Ito et al., 2015). Other studies have also supported this theory 
of developing modified-UCA therapeutics that can be used to protect against UV 
irradiation, without the immunosuppressive effects observed by using normal form cis-
UCA (Mollet et al., 2017). 
 
Non-Melanoma Malignancy 
 
Recall that non-melanoma malignancies refer to skin cancers that do not derive 
from melanocytes, namely base cell and squamous cell carcinomas. To test the 
 46 
association of cis-UCA levels to progression of non-melanoma malignancies in a human 
model, Decara et al. analyzed UCA content in UV-exposed and non-UV-exposed skin 
biopsies of BCC and SCC patients (Decara et al., 2008). Whereas no significant 
differences were found in levels of total UCA concentration in UV-exposed skin sites 
between skin cancer patients and healthy controls, increased concentrations of cis-UCA 
was found specifically in SCC patients, compared to BCC patients and healthy controls 
(Decara et al., 2008). Thus, this suggests that progression of SCC may be linked to cis-
UCA induced immunosuppression.  
Individuals deficient in the histidase gene are expected to have low levels of 
UCA. Thus, researchers have begun to investigate the genetic-environmental relationship 
in individuals with histidase deficiency and exposure to UV irradiation, and its 
subsequent impact on developing non-melanoma skin cancer. In a large 2008 population-
based study, Welsh et al. found that individuals with variation in the histidase gene who 
are exposed to higher lifetime sunburn counts and higher lifetime UV exposures had 
higher risks of developing non-melanoma skin cancers compared to individuals without 
variation in the histidase gene (Welsh et al., 2008).  
Importantly, the connection between UCA and non-melanoma malignancies is not 
yet fully understood. While some studies have found connections between UCA and non-
melanoma malignancies, both negative and positive, others suggest that no connection 
exists. In a 2001 study by De Simone et al., researchers found that the levels of total UCA 
or cis-UCA did not vary significantly between individuals who had non-melanoma skin 
cancers versus healthy controls (De Simone et al., 2001).  
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Figure 5. Different Forms of Skin Cancer. Skin cancers are categorized by their cell of 
origin. There are two main types of skin cancer: melanoma and non-melanoma skin 
cancer. Non-melanoma skin cancers can be further broken in basal cell carcinoma and 
squamous cell carcinoma. Basal cell carcinoma is the most common, followed by 
squamous cell carcinoma. Melanoma is the deadliest form of skin cancer. Taken from 
Kelly, 2018.  
 
Melanoma Malignancy 
 
Melanoma refers to cancerous transformations in melanocyte cells found in the 
skin. The role of cis-UCA in melanoma malignancies remains under debate, but recent 
research has begun to shed light on potential relationships between the two. A 2010 study 
by Laihia et al. tested the protodynamic concept, involving the ability of cis-UCA to 
acidify epidermal microenvironments, in melanoma cancer cell lines and observed the 
resultant effects (Laihia et al., 2010).  Interestingly, application of cis-UCA reduced cell 
counts of human melanoma, cervical carcinoma, and fibrosarcoma cell lines through 
activation of caspase pathways and induction of apoptosis (Laihia et al., 2010). This is 
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one of the few studies that have suggested cis-UCA can serve as an anti-cancerous 
therapeutic agent.  
Particularly in the realm of melanoma malignancies, UCA has generally been 
shown to have more protective effects, compared to deleterious effects. The reasons for 
this remain unknown, but possibilities include variation in the interaction of UCA with 
specific populations of tumor cells, such as melanocytes compared to keratinocytes, and 
variation in the way melanoma and non-melanoma malignancies interact with the 
immune system. A case-control study by Thyssen et al. in 2018 tested a growing theory 
that filaggrin contributes to protection against skin cancer, partially through the filaggrin 
derivative UCA, and that loss of the filaggrin protein through loss-of-function mutations 
would likely increase the risk of malignant transformations in the epidermis (Thyssen et 
al., 2018). However, they found that a loss of function mutation in the filaggrin gene was 
not significantly associated with risk of developing melanoma (Thyssen et al., 2018). 
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CONCLUSION  
 
Despite being a key player within the epidermis, with roles in both physiological 
skin health and in modulation of the immune system, Urocanic acid remains a compound 
that few have heard about. After its discovery in the 1950’s as a novel, endogenous 
photoprotectant, many believed it would be the key to developing cosmetics and 
therapeutics to radically reduce rates of skin cancer. Unfortunately, the discovery that the 
cis-form of Urocanic acid mediates immunosuppression and could contribute to cancer 
cell evasion of the immune system, quickly dispelled those beliefs. After that time, 
scientific investigation around Urocanic acid took a large dip, with only a few studies 
being published every so often. The beginning of the 21st century came with a resurgence 
in research around the endogenous photoprotectant that many had forgotten about. New 
findings, including UCA’s derivation from the filaggrin protein, downregulation of T-
lymphocytes and Langerhans cells by cis-UCA, and interaction with serotonin receptors 
have begun clarifying the physiological role of endogenous UCA, and provide insight 
into methods that therapeutics can be adapted to treat epidermal malignancies. In addition 
to serving a potential measure for efficacy of commercial sunscreens, theories of using 
the IL-12 cytokine to suppress cis-UCA function holds great potential as a means of 
controlling tumor growth in in vivo murine cancer models. Research showing that UCA 
may serve as a biomarker for various skin conditions, including risk of skin cancer, hold 
great promise in improving detection and prevention strategies. Still, a full molecular 
understanding of UCA’s interactions with the integumentary system and the immune 
system is far from being complete. A few studies pointing in a particular direction are 
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unfortunately not enough to draw definitive conclusions from.  Even more, contradictory 
evidence from various studies make drawing conclusions immensely more difficult. A 
prime example analyzed was the effect of UCA on reactive oxygen species, a key cell 
stressor and risk factor for cancerous transformations. Some research has shown that 
trans-UCA is capable of acting as an antioxidant, whereas others have shown cis-UCA 
acting as a contributor to the formation of reactive oxygen species. Clearly, if we are to 
target UCA as a therapeutic for skin cancer, the differences in effects between trans-UCA 
and cis-UCA must be fully elucidated. Another prime example was the varying evidence 
regarding UCA and forms of skin cancer. Cis-UCA seemed to be deleteriously associated 
with non-melanoma skin cancers, thus suggesting cis-UCA should be inhibited if targeted 
for therapeutic intervention. On the other hand, cis-UCA seemed to be protectively 
associated with melanoma skin cancers, which is, in general, in opposition to a large 
majority of the evidence we have seen in regards to cis-UCA and cancerous development. 
Thus, current research has provided extensive knowledge and direction for defining the 
epidermal and immunological pathways UCA plays a role in, but further research must 
focus on solidifying this understanding if UCA is ever to be targeted as a therapeutic for 
melanoma and non-melanoma malignancies.   
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